Scimago Lab
powered by Scopus
call: +1.631.629.4327
Mon-Fri 10 am - 2 pm EST


Medical Science Monitor Basic Research


eISSN: 2329-0358

Get your full text copy in PDF

Results of liver transplantation for hepatocellular cancer

Krzysztof Zieniewicz, Waldemar Patkowski, Paweł Nyckowski, Abdulsalam Alsharabi, Bogdan Michałowicz, Jacek Pawlak, Rafał Paluszkiewicz, Tadeusz Wróblewski, Bogusław Najnigier, Piotr Smoter, Piotr Hevelke, Anna Skwarek, Piotr Remiszewski, Marcin Kotulski, Michał Skalski, Leszek Pączek, Marek Krawczyk

Ann Transplant 2007; 12(1): 11-14

ID: 495357

Background: Liver transplantation (LTx) for hepatocellular carcinoma (HCC) in cirrhotic liver is nowadays generally accepted treatment modality.
Aim of Study: Overview of the indications and results of the LTx in the patients with HCC, the first one performed in 2001.
Material/Methods: Among 357 adult liver transplant recipients in the period 1994–04.2005, in 26 (7%) the indication was HCC (16 men: 10 women, age 20–65, mean 46.5 years). HCC developed in cirrhotic liver in 25 pts. 12 (48%) were Child C, 10 (30%) – Child B and 3 (12%) – Child A patients. As underlying disease in 2 patients (8%) was alcoholic cirrhosis, in 7 (28%) – HBV cirrhosis, in 12 (48%) – HCV cirrhosis and in 4 (16%) – HBV/HCV cirrhosis. Milano criteria were met in 20 patients (77%). The mean waiting list time was 2.9 months (range 1–6 months). Seven patients underwent liver resection and 1 transarterial chemoembolization prior to LTx. 11 patients (42%) were operated on with use of veno-venous bypass, in 15 patients (58%) the piggy back technique was applied. Rapamycine based immunosuppression was preferred in post-LTx treatment.
Results: Operative mortality was 0. 4 patients required relaparotomy for intraperitoneal bleeding. 21 patients (81%) are alive in good general condition, 19 – free of the disease. 5 patients died 7–28 months after LTx (mean 16.7). The mean survival time is 20 months (range 1–38).
Conclusions: Liver transplantation is safe and effective method of treatment of the selected patients with HCC in cirrhotic liver. Further investigations concerning the precise indications, timing of the transplantation and adjuvant treatment are necessary.

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree